PMID- 32753843
OWN - NLM
STAT- MEDLINE
DCOM- 20210604
LR  - 20220416
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 14
DP  - 2020
TI  - The Expression and Therapeutic Potential of Checkpoint Kinase 2 in Laryngeal 
      Squamous Cell Carcinoma.
PG  - 2613-2622
LID - 10.2147/DDDT.S245267 [doi]
AB  - INTRODUCTION: Laryngeal squamous cell carcinoma (LSCC) is the most common 
      histological subtype of laryngeal cancer. The involved molecular mechanisms and 
      suitable therapeutic targets for LSCC still need to be further investigated. 
      Checkpoint kinase 2 (CHK2) participates in several cellular physiology pathways 
      and plays a role in tumor progression. However, the roles of CHK2 in LSCC remain 
      unclear. METHODS: mRNA expression data were obtained from The Cancer Genome Atlas 
      (TCGA) database, and bioinformatic analysis was performed. Western blot and 
      immunohistochemical analyses were conducted to detect protein expression. MTS 
      assays were performed to examine cell growth of LSCC-derived cell lines. RESULTS: 
      In the present study, we found that both active form of CHK2 and total CHK2 
      protein expressions were up-regulated in LSCC tissues. Positive expression of 
      CHK2 was closely associated with advanced clinical features and poor prognosis. 
      Moreover, potential CHK2-involving bioprocesses and signaling pathways were 
      analyzed. In addition, repressed proliferation of LSCC cells was induced by CHK2 
      inhibitor. DISCUSSION: Taken together, our findings elucidated that CHK2 may act 
      as an oncogenic factor in LSCC, suggesting a potential target for clinical 
      treatment.
CI  - (c) 2020 Tian et al.
FAU - Tian, Ying
AU  - Tian Y
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital of China Medical 
      University, Shenyang, People's Republic of China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital of China Medical 
      University, Shenyang, People's Republic of China.
FAU - Xu, Shan
AU  - Xu S
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital of China Medical 
      University, Shenyang, People's Republic of China.
FAU - Guan, Chao
AU  - Guan C
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital of China Medical 
      University, Shenyang, People's Republic of China.
FAU - Zhang, Qingfu
AU  - Zhang Q
AD  - Department of Pathology, The First Affiliated Hospital and College of Basic 
      Medical Sciences of China Medical University, Shenyang, People's Republic of 
      China.
FAU - Li, Wei
AU  - Li W
AUID- ORCID: 0000-0001-9368-3397
AD  - Department of Otorhinolaryngology, The First Affiliated Hospital of China Medical 
      University, Shenyang, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200706
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.1.11 (Checkpoint Kinase 2)
RN  - EC 2.7.11.1 (CHEK2 protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/drug therapy/*metabolism/pathology
MH  - Cell Proliferation/drug effects
MH  - Checkpoint Kinase 2/analysis/antagonists & inhibitors/*metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/drug therapy/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - RNA, Messenger/analysis/antagonists & inhibitors/metabolism
MH  - Tumor Cells, Cultured
PMC - PMC7351626
OTO - NOTNLM
OT  - BML-277
OT  - checkpoint kinase 2
OT  - laryngeal squamous cell carcinoma
OT  - tumor growth
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/08/06 06:00
MHDA- 2021/06/05 06:00
PMCR- 2020/07/06
CRDT- 2020/08/06 06:00
PHST- 2020/01/08 00:00 [received]
PHST- 2020/06/12 00:00 [accepted]
PHST- 2020/08/06 06:00 [entrez]
PHST- 2020/08/06 06:00 [pubmed]
PHST- 2021/06/05 06:00 [medline]
PHST- 2020/07/06 00:00 [pmc-release]
AID - 245267 [pii]
AID - 10.2147/DDDT.S245267 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2020 Jul 6;14:2613-2622. doi: 10.2147/DDDT.S245267. 
      eCollection 2020.